CrkL activates integrin-mediated hematopoietic cell adhesion through the guanine nucleotide exchange factor C3G

Blood

Volumn 93, Issue 11, 1999, Pages 3713-3722

  Arai, Ayako ^a   Nosaka, Yurika ^a   Kohsaka, Hitoshi ^a   Miyasaka, Nobuyuki ^a   Miura, Osamu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MUTANT PROTEIN; VERY LATE ACTIVATION ANTIGEN 5;

ARTICLE; CELL ADHESION; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 0033152359     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.11.3713     Document Type: Article

References (59)

1. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11, 1992
2. Clark EA, Brugge JS: Integrins and signal transduction pathways: The road taken. Science 268:233, 1995
3. Rosemblatt M, Vuillet GM, Leroy C, Coulombel L: Coexpression of two fibronectin receptors, VLA-4 and VLA-5, by immature human erythroblastic precursor cells. J Clin Invest 87:6, 1991
4. Williams DA, Rios M, Stephens C, Patel VP: Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature 352:438, 1991
5. Kerst JM, Sanders JB, Slaper-Cortenbach ICM, Doorakkers MCH, Hooibrink B, van Oers RJH, Von dem Borne AEG Kr, van der Schoot Ce: Alpha 4 beta 1 and alpha 5 beta 1 are differentially expressed during myelopoiesis and mediate the adherence of human CD34+ cells to fibronectin in an activation-dependent way. Blood 81:344, 1993
6. Levesque JP, Leavesley DI, Niutta S, Vadas M, Simmons PJ: Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med 181:1805, 1995
7. Kovach NL, Lin N, Yednock T, Harlan JM, Broudy VC: Stem cell factor modulates avidity of alpha 4 beta 1 and alpha 5 beta 1 integrins expressed on hematopoietic cell lines. Blood 85:159, 1995
8. Levesque JP, Haylock DN, Simmons PJ: Cytokine regulation of proliferation and cell adhesion are correlated events in human CD34+ hemopoietic progenitors. Blood 88:1168, 1996
9. Gotoh A, Ritchie A, Takahira H, Broxmeyer HE: Thrombopoietin and erythropoietin activate inside-out signaling of integrin and enhance adhesion to immobilized fibronectin in human growth-factor-dependent hematopoietic cells. Ann Hematol 75:207, 1997
10. Verfaillie CM, McCarthy JB, McGlave PB: Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 174:693, 1991
11. Miyake K, Weissman IL, Greenberger JS, Kincade PW: Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J Exp Med 173:599, 1991
12. Papayannopoulou T, Nakamoto B: Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 90:9374, 1993
13. Yanai N, Sekine C, Yagita H, Obinata M: Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. Blood 83:2844, 1994
14. Sugahara H, Kanakura Y, Furitsu T, Ishihara K, Oritani K, Ikeda H, Kitayama H, Ishikawa J, Hashimoto K, Kanayama Y, Matsuzawa Y: Induction of programmed cell death in human hematopoietic cell lines by fibronectin via its interaction with very late antigen 5. J Exp Med 179:1757, 1994
15. Hirsch E, Iglesias A, Potocnik AJ, Hartmann U, Fassler R: Impaired migration but not differentiation of haematopoietic stem cells in the absence of betal integrins. Nature 380:171, 1996
16. Strobel ES, Mobest D, von KS, Dangel M, Ries S, Mertelsmann R, Henschler R: Adhesion and migration are differentially regulated in hematopoietic progenitor cells by cytokines and extracellular matrix. Blood 90:3524, 1997
17. Schofield KP, Humphries MJ, de Wynter E, Testa N, Gallagher JT: The effect of alpha4 beta1-integrin binding sequences of fibronectin on growth of cells from human hematopoietic progenitors. Blood 91:3230, 1998
18. Yokota T, Oritani K, Mitsui H, Aoyama K, Ishikawa J, Sugahara H, Matsumura I, Tsai S, Tomiyama Y, Kanakura Y, Matsuzawa Y: Growth-supporting activities of fibronectin on hematopoietic stem/ progenitor cells in vitro and in vivo: Structural requirement for fibronectin activities of CS1 and cell-binding domains. Blood 91:3263, 1998
19. Mayer BJ, Hamaguchi M, Hanafusa H: A novel viral oncogene with structural similarity to phospholipase C. Nature 332:272, 1988
20. Matsuda M, Tanaka S, Nagata S, Kojima A, Kurata T, Shibuya M: Two species of human CRK cDNA encode proteins with distinct biological activities. Mol Cell Biol 12:3482, 1992
21. ten Hoeve J, Morris C, Heisterkamp N, Groffen J: Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene 8:2469, 1993
22. Tanaka S, Morishita T, Hashimoto Y, Hattori S, Nakamura S, Shibuya M, Matuoka K, Takenawa T, Kurata T, Nagashima K, Matsuda M: C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. Proc Natl Acad Sci USA 91:3443, 1994
23. Feller SM, Knudsen B, Hanafusa H: Cellular proteins binding to the first Src homology 3 (SH3) domain of the proto-oncogene product c-Crk indicate Crk-specific signaling pathways. Oncogene 10:1465, 1995
24. de Jong R, Haataja L, Voncken JW, Heisterkamp N, Groffen J: Tyrosine phosphorylation of murine Crkl. Oncogene 11:1469, 1995
25. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ: Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269:22925, 1994
26. ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J: Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 84:1731, 1994
27. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW: Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 84:2912, 1994
28. de Jong R, ten Hoeve J, Heisterkamp N, Groffen J: Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. Oncogene 14:507, 1997
29. Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV, Griffin JD: Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem 272:10248, 1997
30. Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H, Wakui M, Handa M, Watanabe K, Okamoto S, Ikeda Y: Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood 88:4304, 1996
31. Chin H, SaitoT, Arai A, Yamamoto K, Kamiyama R, Miyasaka N, Miura O: Erythropoietin and IL-3 induce tyrosine phosphorylation of CrkL and its association with Shc, SHP-2, and Cbl in hematopoietic cells. Biochem Biophys Res Commun 239:412, 1997
32. Gesbert F, Garbay C, Bertoglio J: Interleukin-2 stimulation induces tyrosine phosphorylation of p120-Cbl and CrkL and formation of multimolecular signaling complexes in T lymphocytes and natural killer cells. J Biol Chem 273:3986, 1998
33. Barber DL, Mason JM, Fukazawa T, Reedquist KA, Druker BJ, Band H, D'Andrea AD: Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood 89:3166, 1997
34. Miura O, Cleveland JL, Ihle JN: Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors. Mol Cell Biol 13:1788, 1993
35. ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N, Groffen J: Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res 54:2563, 1994
36. Sells MA, Chernoff J: Epitope-tag vectors for eukaryotic protein production. Gene 152:187, 1995
37. Bonner TI, Oppermann H, Seeburg P, Kerby SB, Gunnell MA, Young AC, Rapp UR: The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene. Nucleic Acids Res 14:1009, 1986
38. Zhang Z, Vuori K, Wang H, Reed JC, Ruoslahti E: Integrin activation by R-ras. Cell 85:61, 1996
39. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:5547, 1992
40. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, Miura O: Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 91:3734, 1998
41. Kimura M, Takatsuki A, Yamaguchi I: Blasticidin S deaminase gene from Aspergillus terreus (BSD): A new drug resistance gene for transfection of mammalian cells. Biochem Biophys Acta 1219:653, 1994
42. Chin H, Nakamura N, Kamiyama R, Miyasaka N, Ihle JN, Miura O: Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3. Blood 88:4415, 1996
43. Hughes PE, Renshaw MW, Pfaff M, Forsyth J, Keivens VM, Schwartz MA, Ginsberg MH: Suppression of integrin activation: A novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88:521, 1997
44. Senechal K, Heaney C, Druker B, Sawyers CL: Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Mol Cell Biol 18:5082, 1998
45. Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB, Groffen J, Griffin JD: CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 270:29145, 1995
46. Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD: p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem 271:25198, 1996
47. de Jong R, van Wijk A, Haataja L, Heisterkamp N, Groffen J: BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl. J Biol Chem 272:32649, 1997
48. Sattler M, Salgia R, Shrikhande G, Verma S, Uemura N, Law SF, Golemis EA, Griffin JD: Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem 272:14320, 1997
49. de Jong R, ten Hoeve J, Heisterkamp N, Groffen J: Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 270:21468, 1995
50. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD: The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 12:839, 1996
51. Senechal K, Halpera J, Sawyers CL: The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem 271:23255, 1996
52. Gotoh T, Niino Y, Tokuda M, Hatase O, Nakamura S, Matsuda M, Hattori S: Activation of R-Ras by Ras-guanine nucleotide-releasing factor. J Biol Chem 272:18602, 1997
53. Cook SJ, Rubinfeld B, Albert I, McCormick F: RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts. EMBO J 12:3475, 1993
54. Kitayama H, Sugimoto Y, Matsuzaki T, Ikawa Y, Noda M: A ras-related gene with transformation suppressor activity. Cell 56:77, 1989
55. Sakoda T, Kaibuchi K, Kishi K, Kishida S, Doi K, Hoshino M, Hattori S, Takai Y: smg/rap1/Krev-1 p21s inhibit the signal pathway to the c-fos promoter/enhancer from c-Ki-ras p21 but not from c-raf-1 kinase in NIH3T3 cells. Oncogene 7:1705, 1992
56. Laudanna C, Campbell JJ, Butcher EC: Role of Rho in chemoattractant-activated leukocyte adhesion through integrins. Science 271: 981, 1996
57. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV: Cdc42 and Racl induce integral-mediated cell motility and invasiveness through PI(3)K. Nature 390:632, 1997
58. Altun-Gultekin Z, Chandriani S, Bougeret C, Ishizaki T, Narumiya S, de Graaf P, van Bergen en Henegouwen P, Hanafusa H, Wagner JA, Birge RB: Activation of Rho-dependent cell spreading and focal adhesion biogenesis by the v-Crk adaptor protein. Mol Cell Biol 18:3044, 1998
59. Manie SN, Beck A, Astier A, Law SF, Canty T, Hirai H, Druker BJ, Avraham H, Haghayeghi N, Sattler M, Salgia R, Griffin JD, Golemis EA, Freedman AS: Involvement of p130(Cas) and p105(HEF1), a novel cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem 272:4230, 1997